Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P910056/S066

enVista Hydrophobic Acrylic Intraocular Lens

Bausch + Lomb, Inc. · Decision date Oct 14, 2026

MEDTECHLEDGER EXPLANATIONP910056/S066

What did the FDA decide?

The FDA record P910056/S066 for the enVista Hydrophobic Acrylic Intraocular Lens lists an OK30 decision dated 2026-10-14 under a 30-Day Notice. The supplement reason is a process change covering manufacturer, sterilizer, packager or supplier, and the stated change is increasing the production lot size and extending the unrefrigerated holding time. The notice does not name the affected manufacturing site, the prior and proposed lot sizes, or the previous and new holding durations.

The identifier ties the notice to PMA P910056 as supplement S066. An OK30 action on a 30-day notice is not an approval of the original PMA or of the whole lens system, and the source statement's reported purpose is not independent proof of safety or clinical effectiveness. The record carries no new indication, clinical data or performance result, and none should be inferred.

FDA approval order statement

increasing the production lot size and extending the unrefrigerated holding time
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Oct 14, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P910056/S066
Regulatory pathway
PMA supplement
Product code
HQL
Decision code
OK30
Decision date
Oct 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: intraocular lens.

Product code
HQL
FDA device class
3

For the original device and its historical approval scope, see PMA P910056. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P910056 · Original PMA

    SOFLEX UV-ABSORBING SILICONE POSTERIOR CHAMBER INTRAOCULAR LENS

  2. P910056/S063 · Related supplement

    enVista hydrophobic acrylic intraocular lens

  3. P910056/S066 received

    Application receipt date recorded by FDA.

  4. P910056/S065 · Related supplement

    enVista Aspire Hydrophobic Acrylic Intraocular Lens (IOL)

  5. P910056/S064 · Related supplement

    enVista Hydrophobic Acrylic Intraocular Lens

  6. P910056/S066 · FDA decision

    30-Day Notice

  7. P910056/S067 · Related supplement

    enVista Hydrophobic Acrylic Intraocular Lens

Timeline entries are records held by MedtechLedger for P910056. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P910056

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch + Lomb, Inc.PMA approvalJan 17, 1992FDA
Bausch + Lomb, Inc.PMA supplementSep 3, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 29, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 30, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code HQL

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bausch + Lomb, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
50 Technology Dr., Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records